With the aid of Operation Warp Speed funding, #NVAX is committed to delivering 100 million doses of our #vaccine candidate starting by the end of the year. Thank you to @FujifilmDiosyn for hosting us with President Donald J. Trump and members of the administration today. $NVAX #NVXCoV2373

We just announced the publication of a nonhuman primate preclinical viral challenge study of mRNA-1273 in NEJM. Read more: buff.ly/30YfDxh

The New Yorker takes a peek inside B.U.'s National Emerging Infectious Diseases Laboratories, a hub for coordinating coronavirus research: bit.ly/2WTCadB

We have some big news coming this week... stay tuned to find out!

Happy to announce the launch of University of MichiganChE professor Lola Eniola-Adefeso's new @UMich startup Asalyxa Bio to advance her potential therapy for Acute Respiratory Distress Syndrome (#ARDS), the leading cause of death among #COVID19 patients. Grove bio news.umich.edu/u-m-spinout-as…

The Grove bio release: globenewswire.com/news-release/2…

Been recently following what Marc Appel and team is creating at Orange Grove Bio. Recently started trial for their first drug candidate with more to come. globenewswire.com/fr/news-releas… Grove bio

Listen to our founder Marc Appel speak about innovation and driving factors in the biotech industry with Mark Bayer, link is in our bio. instagram.com/p/CEuDaMxBnXN/…

Today is #RareDiseaseDay! There are over 6⃣0⃣0⃣0⃣ rare diseases 🌏 300 million people live with a rare disease accross the world Rare diseases currently affect 3.5% - 5.9% of the worldwide population👨‍👩‍👧‍👦 Learn more about what is a #raredisease 👉rarediseaseday.org/article/what-i…

On this Rare Disease Day, families just like the Harrisons are fighting to raise awareness for rare diseases that affect 300 million people across the world. To show your support, visit RareDiseaseDay.org thedenverchannel.com/news/local-new…

Humbled to be featured in the WSJ. Looking forward to working with scientists on the forefront of biotech innovation. #wsj #Biotech #VentureCapital wsj.com/articles/vc-da…

Proud to announce that our first portfolio company asalyxabio has successfully raised seed funding and will now be headed to the clinic. #clinicaltrials #Biotech prnewswire.com/news-releases/…

Check out this piece about our portfolio company, Asalyxa Bio, in the Cronicle featuring our CEO, Marc Appel. cronicle.press/2021/03/08/ann…

Check out this article written about our portfolio company asalyxabio highlighting the findings of Asalyxa's CSO, @Lola_UMich prnewswire.com/news-releases/…

Just posted a photo instagram.com/p/CP_dACEhKsW/…

We’re excited to announce the launch of the pilot episode of ‘From The Patient's Eyes,’ brought to you by Orange Grove Bio and the Autoimmune Registry to feature the story of Stephanie Giguere, a patient suffering from Ankylosing Spondylitis. open.spotify.com/show/0tSRtB4tF…

This episode of From The Patient's Eyes is brought to you by Orange Grove Bio and the Autoimmune Registry to feature autoimmune patient Julianne Larkin as she shares her experiences as an individual diagnosed with Graves' disease and, later, arthritis. open.spotify.com/episode/1l7pvr…

Today we're launching our rebrand. As our business has grown, we have evolved. Our new look represents the expression of that journey and our next chapter. We might look different, but our mission remains the same. orangegrovebio.com #orangegrovebio #biotech #rebrand